English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE I CLINICAL TRIAL OF JSKN003 (KN026-ADC) IN AUSTRALIA FOR THE TREATMENT OF ADVANCED SOLID TUMORS
2022-09-19
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
2022-09-06
VOLUNTARY ANNOUNCEMENT - UPDATES ON CLINICAL DATA OF KN046 AND KN026 FOR PRESENTATION AT ESMO CONGRESS 2022
2022-09-05
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022
2022-08-31
Date of Board Meeting
2022-08-18
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II CLINICAL TRIAL OF KN046 COMBINED WITH AXITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED NSCLC
2022-08-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
2022-08-03
VOLUNTARY ANNOUNCEMENT - ABSTRACTS AND E-POSTERS OF RESEARCH UPDATES ON KN046 AND KN026 FOR PRESENTATION AT ESMO CONGRESS 2022
2022-07-29
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022
2022-07-07
RESIGNATION OF A NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTE
2022-06-16
10
11
12
13
14
15
16
PREV
13/27
NEXT